123 related articles for article (PubMed ID: 29305520)
1. Soluble SLAMF6 Receptor Induces Strong CD8
Eisenberg G; Engelstein R; Geiger-Maor A; Hajaj E; Merims S; Frankenburg S; Uzana R; Rutenberg A; Machlenkin A; Frei G; Peretz T; Lotem M
Cancer Immunol Res; 2018 Feb; 6(2):127-138. PubMed ID: 29305520
[TBL] [Abstract][Full Text] [Related]
2. Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions.
Hajaj E; Zisman E; Tzaban S; Merims S; Cohen J; Klein S; Frankenburg S; Sade-Feldman M; Tabach Y; Yizhak K; Navon A; Stepensky P; Hacohen N; Peretz T; Veillette A; Karni R; Eisenberg G; Lotem M
Cancer Immunol Res; 2021 Jun; 9(6):637-650. PubMed ID: 33762352
[TBL] [Abstract][Full Text] [Related]
3. SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint.
Hajaj E; Eisenberg G; Klein S; Frankenburg S; Merims S; Ben David I; Eisenhaure T; Henrickson SE; Villani AC; Hacohen N; Abudi N; Abramovich R; Cohen JE; Peretz T; Veillette A; Lotem M
Elife; 2020 Mar; 9():. PubMed ID: 32122464
[TBL] [Abstract][Full Text] [Related]
4. SLAMF6 as a Regulator of Exhausted CD8
Yigit B; Wang N; Ten Hacken E; Chen SS; Bhan AK; Suarez-Fueyo A; Katsuyama E; Tsokos GC; Chiorazzi N; Wu CJ; Burger JA; Herzog RW; Engel P; Terhorst C
Cancer Immunol Res; 2019 Sep; 7(9):1485-1496. PubMed ID: 31315913
[TBL] [Abstract][Full Text] [Related]
5. SLAMF6 clustering is required to augment T cell activation.
Dragovich MA; Adam K; Strazza M; Tocheva AS; Peled M; Mor A
PLoS One; 2019; 14(6):e0218109. PubMed ID: 31199820
[TBL] [Abstract][Full Text] [Related]
6. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
[TBL] [Abstract][Full Text] [Related]
8. Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation.
Li SY; Liu Y; Xu CF; Shen S; Sun R; Du XJ; Xia JX; Zhu YH; Wang J
J Control Release; 2016 Jun; 231():17-28. PubMed ID: 26829099
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
10. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
11. Rescue of tumor-infiltrating lymphocytes from activation-induced cell death enhances the antitumor CTL response in CD5-deficient mice.
Tabbekh M; Franciszkiewicz K; Haouas H; Lécluse Y; Benihoud K; Raman C; Mami-Chouaib F
J Immunol; 2011 Jul; 187(1):102-9. PubMed ID: 21622855
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of in vitro tumor-infiltrating lymphocyte cytotoxicity by heteroconjugated antibodies.
Reid I; Lundy J; Donohue JH
J Immunol; 1992 Apr; 148(8):2630-5. PubMed ID: 1532818
[TBL] [Abstract][Full Text] [Related]
13. Multifaceted Role of BTLA in the Control of CD8
Ritthipichai K; Haymaker CL; Martinez M; Aschenbrenner A; Yi X; Zhang M; Kale C; Vence LM; Roszik J; Hailemichael Y; Overwijk WW; Varadarajan N; Nurieva R; Radvanyi LG; Hwu P; Bernatchez C
Clin Cancer Res; 2017 Oct; 23(20):6151-6164. PubMed ID: 28754817
[No Abstract] [Full Text] [Related]
14. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
15. Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma.
Bertrand F; Rochotte J; Colacios C; Montfort A; Tilkin-Mariamé AF; Touriol C; Rochaix P; Lajoie-Mazenc I; Andrieu-Abadie N; Levade T; Benoist H; Ségui B
Cancer Res; 2015 Jul; 75(13):2619-28. PubMed ID: 25977337
[TBL] [Abstract][Full Text] [Related]
16. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.
Ahern E; Harjunpää H; Barkauskas D; Allen S; Takeda K; Yagita H; Wyld D; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2017 Oct; 23(19):5789-5801. PubMed ID: 28634284
[No Abstract] [Full Text] [Related]
17. Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.
Velicu S; Han Y; Ulasov I; Brown IE; El Andaloussi A; Gajewski TF; Lesniak MS
J Neuroimmunol; 2006 May; 174(1-2):74-81. PubMed ID: 16504307
[TBL] [Abstract][Full Text] [Related]
18. Cytokine-like molecule CCDC134 contributes to CD8⁺ T-cell effector functions in cancer immunotherapy.
Huang J; Xiao L; Gong X; Shao W; Yin Y; Liao Q; Meng Y; Zhang Y; Ma D; Qiu X
Cancer Res; 2014 Oct; 74(20):5734-45. PubMed ID: 25125657
[TBL] [Abstract][Full Text] [Related]
19. Deletion of MyD88 in T Cells Improves Antitumor Activity in Melanoma.
Bayer AL; Padilla-Rolon D; Smolgovsky S; Hinds PW; Alcaide P
Am J Pathol; 2024 Jun; 194(6):1007-1019. PubMed ID: 38442804
[TBL] [Abstract][Full Text] [Related]
20. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
